| Literature DB >> 20098598 |
Anthony D Wright1, Jonathan L Nielson, Dianne M Tapiolas, Cherie A Motti, Simon P B Ovenden, Philip S Kearns, Catherine H Liptrot.
Abstract
From the dichloromethane/methanol extract of the crinoid Colobometra perspinosa, collected south east of Richards Island (Bedara), Family Islands, Central Great Barrier Reef, Australia, 3-(1'-hydroxypropyl)-1,6,8-trihydroxy-9,10-anthraquinone [one of the two stereoisomers of rhodoptilometrin, (1)], 3-propyl-1,6,8-trihydroxy-9,10-anthraquinone (3), 2-[(phenylacetyl)amino]ethanesulfonic acid (4), and 4-hydroxybutanoic acid (5) were isolated. Comparison of (1)H- and (13)C-NMR data for rhodoptilometrin (1) with those reported in the literature showed significant differences for some resonances associated with rings A and C. In an attempt to provide accurately assigned (1)H- and (13)C-NMR data, as well as to confirm the structure of 1, a thorough NMR investigation of this compound was undertaken. Measurements included: concentration dependent (13)C, 1D selective NOE, HSQC, HMBC and 1,1-ADEQUATE. The NMR data for 4 and 5 are reported here for the first time, as is their occurrence from the marine environment. The in vitro anticancer activity of the original extract was found to be associated with 1, 3 and 5.Entities:
Keywords: 1,1-ADEQUATE; Colobometra perspinosa; NMR; anticancer; echinoderm; marine natural products
Mesh:
Substances:
Year: 2009 PMID: 20098598 PMCID: PMC2810237 DOI: 10.3390/md7040565
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Comparison of NMR data for 1 isolated in the current study (1H-NMR at 600 MHz, 13C-NMR at 150 MHz, basic frequency) with that reported previously for 1 [8–10] and with 3.
| No. | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 163.7 (s) | 163.6 (s) | 163.6 (s) | ||||||||
| 2 | 122.4 (d) | 122.3 (d) | 124.7 (d) | 7.20 (s) | 7.24 (d, 1.4) | 7.17 (brs) | 7.24 (d, 1.4) | 6.73 (d, 1.2) | C-4, 1’ | C-1’, 1, 3, 4, 9a | C-1, 3 |
| 3 | 156.1 (s) | 156.6 (s) | 154.2 (s) | ||||||||
| 4 | 116.6 (d) | 118.4 (d) | 121.2 (d) | 7.70 (s) | 7.72 (d, 1.4) | 7.56 (brs) | 7.66 (d, 1.4) | 7.16 (d, 1.2) | C-2, 10, 1’ | C-1’, 1, 2, 9, 9a, 10 | C-3, 4a |
| 4a | 135.3 (s) | 134.9 (s) | 134.7 (s) | ||||||||
| 5 | 113.6 (d) | 110.4 (d) | 109.1 (d) | 7.09 (s) | 7.16 (d, 2.4) | 6.96 (d, 2.0) | 7.02 (d, 2.5) | 6.61 (d 2.0) | C-10 | C-6, 7, 8, 8a, 9, 10 | C-6, 10a |
| 6 | 160.2 (s) | 166.7 (s) | 166.6 (s) | ||||||||
| 7 | 109.7 (d) | 109.1 (d) | 110.1 (d) | 6.35 (d, 3.4) | 6.52 (d, 2.4) | 6.41 (d 2.0) | 6.44 (d, 2.5) | 6.02 (d, 2.0) | C-5 | C-5, 6, 8, 8a | C-6 |
| 8 | 167.5 (s) | 167.9 (s) | 167.2 (s) | ||||||||
| 8a | 113.9 (s) | 110.5 (s) | 110.5 (s) | ||||||||
| 9 | 192.0 (s) | 191.7 (s) | 191.9 (s) | ||||||||
| 9a | 118.4 (s) | 115.9 (s) | 115.0 (s) | ||||||||
| 10 | 184.3 (s) | 183.2 (s) | 183.2 (s) | ||||||||
| 10a | 136.9 (s) | 136.9 (s) | 136.9 (s) | ||||||||
| 1′ | 75.5 (d) | 75.4 (d) | 39.2 (t) | 4.60 (m) | 4.62 (t, 6.4) | 4.56 (m) | 4.57 (t, 6.5) | 4.19 (t, 5.8) | C-2, 4 | C-2’, 3’, 2, 3, 4 | C-2’, 3 |
| 2′ | 32.6 (t) | 32.6 (t) | 24.8 (t) | 1.73 (m) | 1.75 (m) | 1.65 (m) | 1.63 (m) | C-3, 3′ | C-1’, 3’, 3 | C-1’, 3’ | |
| 3′ | 10.3 (q) | 10.2 (q) | 14.0 (q) | 0.94 (t, 12.5) | 0.96 (t, 7.6) | 0.91 (t, 8.0) | 0.86 (t, 7.3) | C-1’, 2′ | C-1’, 2’ | C-2’ | |
Measured in CD3OD, referenced to internal solvent signals (δ 3.31 and 49.0 ppm).
Measured in DMSO d6, referenced to internal solvent signals (δ2.50).
Measured in (CD3)2CO, referenced to TMS (δ0).
NMR resonances and coupling constants associated with atoms at these positions are not consistent with the current molecule and the previously reported rhodoptilometrin [10] being identical.
Data comes from references [8–10], see main text.
Figure 1.Structures of compounds 1–5.
13C-NMR (600 MHz, CD3OD, 298 K) data for 1 (rhodoptilometrin) at various concentrations.
| 1 | 163.7 (s) | 163.6 (s) | 163.4 (s) | 163.5 (s) | 163.6 (s) | 163.7 (s) |
| 2 | 122.4 (d) | 122.3 (d) | 122.2 (d) | 122.2 (d) | 122.3 (d) | 122.3 (d) |
| 3 | 156.1 (s) | 156.6 (s) | 156.5 (s) | 156.6 (s) | 156.6 (s) | 156.7 (s) |
| 4a | 135.3 (s) | 134.9 (s) | 134.5 (s) | 134.7 (s) | 134.8 (s) | 134.8 (s) |
| 7 | 109.7 (d) | 109.1 (d) | 109.0 (d) | 109.0 (d) | 109.0 (d) | 109.1 (d) |
| 8 | 167.5 (s) | 167.9 (s) | 167.1 (s) | 167.2 (s) | 167.3 (s) | 167.4 (s) |
| 9 | 192.0 (s) | 191.7 (s) | 191.5 (s) | 191.7 (s) | 191.8 (s) | 191.9 (s) |
| 10 | 184.3 (s) | 183.2 (s) | 182.7 (s) | 182.9 (s) | 183.0 (s) | 183.1 (s) |
| 10a | 136.9 (s) | 136.9 (s) | 136.6 (s) | 136.7 (s) | 136.9 (s) | 137.0 (s) |
| 1′ | 75.5 (d) | 75.4 (d) | 75.4 (d) | 75.4 (d) | 75.4 (d) | 75.4 (d) |
| 2′ | 32.6 (t) | 32.6 (t) | 32.6 (t) | 32.6 (t) | 32.6 (t) | 32.6 (t) |
| 3′ | 10.3 (q) | 10.2 (q) | 10.2 (q) | 10.2 (q) | 10.2 (q) | 10.2 (q) |
Data from reference [10].
Highlighted rows show ppm values with largest discrepancies from values published in reference [10].
Figure 2.1,1-ADEQUATE spectrum of 1 (600 MHz basic frequency, CD3OD).
GI50 (μM) data for 1, and 3–5 against a series of human tumour cell lines.
| 41 | 21 | 25 | |
| 72 | 20 | 25 | |
| >250 | 195 | >250 | |
| 68 | 32 | 50 |
SF-268 Central nervous system-glioblastoma cells.
MCF-7 Breast-pleural effusion adenocarcinoma cells.
H460 Lung-large cell carcinoma cells.